FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, is excited to share that their European patent for SCFI has been granted!

SCFI, or Sub-Cellular Fluctuation Imaging, is a new way to test how bacteria respond to antibiotics. Created by researchers at the University of Bristol and licensed to FluoretiQ, this technology uses a special optical system and machine learning to see tiny movements in bacterial cells. In just 30 minutes, SCFI can show if bacteria are alive, dead, or dying, helping doctors choose the best antibiotics quickly.

Josephine Dorh, Founder and CTO of FluoretiQ, says:

“SCFI is a game changer for using antibiotics accurately and quickly. We’re excited to bring more life-saving products from this technology.”

Next, FluoretiQ will develop a point-of-care system to make SCFI one of the fastest and most accurate tests for antibiotic effectiveness. They thank Stu Latham and Withers & Rogers for their help with the patent.

Follow FluoretiQ on LinkedIn for more updates!